header logo en

 

10 facts web

 


MK-3475 - 031

 
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer
 
 
 Last updated: January 26, 2017
 STATUS: Recruiting (accepting new patients) (per ClinicalTrials.gov/NCT02212730)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

  • newly diagnosed RCC
  • primary tumour diameter of more than 4 cm (>= T1b)
  • not previously treated
  • candidate for operative tumour resection
  • overall health status has to be good (ECOG 1 or 0)

WHAT

is the key question that this trial is attempting to answer?

This phase I study seeks to clarify whether new immunotherapies are effective in kidney cancer.

It will examine the effect of a treatment with the antibody pembrolizumab on tumours of participants with renal cell cancer (RCC). Pembrolizumab will be given before surgery. After tumour-removal the tumour tissues will be examined to determine the impact of the medication on tumour cells.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

The study is open (recruiting) – 36 patients are currently expected to participate.

WHERE

is the trial available?

The trial will be available in Belgium and Canada.
Contact details:
Toll Free Number 1-888-577-8839

Belgium:
MSD Belgium BVBA/SPRL Recruiting
Brussels, Belgium
Contact: Marc Denayer 32 2 776 60 28

STUDY

DESIGN

What does the study look like?

There will be 2 study arms (groups): all participating patients will be randomly divided (by a computer) in two groups.

Patients in group one will be given pembrolizumab (Keytruda™) followed by surgery:
Participants in group two will get the so called “standard of care” which is surgical resection of the tumour without prior drug treatment.
MK3475-031
 

1) Participants will receive pembrolizumab, 200 mg intravenously every 3-week cycle for up to 3 cycles followed by standard of care (SOC) surgical resection.

2) Participants will receive SOC surgical resection.

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
 
Back to clinical trials overview: How can I find an IO clinical trial for my cancer?